Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 555 Heritage Drive, Suite 200 JUPITER FL 33458 |
Tel: | N/A |
Website: | https://www.ligand.com |
IR: | See website |
Key People | ||
Matthew Edward Korenberg President, Chief Operating Officer | Todd C. Davis Chief Executive Officer, Director | Octavio Espinoza Chief Financial Officer | Andrew Reardon Chief Legal Officer |
Business Overview |
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. |
Financial Overview |
For the three months ended 31 March 2024, Ligand Pharmaceuticals Inc revenues decreased 30% to $31M. Net income before extraordinary items increased 98% to $86.1M. Revenues reflect Milestone segment decrease of 95% to $727K, Teriparatide injection segment decrease of 42% to $2M. Net income reflects Gain from short-term investments increase from $39.5M to $110.8M (income), Other General and administrative decrease of 35% to $4.3M (expense). |
Employees: | 58 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,257M as of Mar 31, 2024 |
Annual revenue (TTM): | $118.31M as of Mar 31, 2024 |
EBITDA (TTM): | $34.39M as of Mar 31, 2024 |
Net annual income (TTM): | $96.34M as of Mar 31, 2024 |
Free cash flow (TTM): | -$27.58M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 17,963,653 as of May 6, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |